Muscular Dystrophy Canada’s “Walk & Roll” events taking place in-person across Canada
For the first time since 2019, Muscular Dystrophy Canada (MDC) will host their annual ‘Walk & Roll for Muscular Dystrophy Canada’ event in person! This year, instead of hosting the event on one specific day nation-wide, Walk & Roll events will take place on different days from May to October at different locations in each province.
Sign up as an individual or with your clinical or research teams to attend one of the in-person events where you will meet patients, families, and other neuromuscular researchers and clinicians, all to raise awareness, funds, and support for the neuromuscular community.
Dates and times
- Montreal, QC | May 27th, 2023
- Edmonton, AB | June 3rd, 2023
- Ottawa, ON | June 11th, 2023
- Toronto, ON | June 24th, 2023
- Vancouver/Burnaby, BC | September 16th, 2023
- Calgary, AB | October 7th, 2023
If you don’t see your city, check out the full list of the 33 Walk & Roll events taking place across Canada to find your nearest event!
To learn more, please contact <>
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.